BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7542138)

  • 21. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
    Kane CJ; Amling CL; Johnstone PA; Pak N; Lance RS; Thrasher JB; Foley JP; Riffenburgh RH; Moul JW
    Urology; 2003 Mar; 61(3):607-11. PubMed ID: 12639656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The staging pelvic lymphadenectomy: implications as an adjunctive procedure for clinically localized prostate cancer.
    Alagiri M; Colton MD; Seidmon EJ; Greenberg RE; Hanno PM
    Br J Urol; 1997 Aug; 80(2):243-6. PubMed ID: 9284196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Staging pelvic lymphadenectomy for prostatic carcinoma].
    Taguchi K; Kumamoto Y; Tsukamoto T; Yamazaki K; Shibuya A; Takahashi A; Takatsuka K; Takagi Y
    Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2124-30. PubMed ID: 8309119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer.
    Wyler SF; Sulser T; Seifert HH; Ruszat R; Forster TH; Gasser TC; Bachmann A
    Urology; 2006 Oct; 68(4):883-7. PubMed ID: 17070376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients.
    Ritenour CW; Abbott JT; Goodman M; Alazraki N; Marshall FF; Issa MM
    ScientificWorldJournal; 2009 Oct; 9():1040-5. PubMed ID: 19802499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection.
    Briganti A; Abdollah F; Nini A; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni NM; Salonia A; Colombo R; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Jun; 61(6):1132-8. PubMed ID: 22099610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy.
    Okotie OT; Aronson WJ; Wieder JA; Liao Y; Dorey F; DeKERNION JB; Freedland SJ
    J Urol; 2004 Jun; 171(6 Pt 1):2260-4. PubMed ID: 15126798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using prostate-specific antigen to eliminate the staging radionuclide bone scan.
    Lee CT; Oesterling JE
    Urol Clin North Am; 1997 May; 24(2):389-94. PubMed ID: 9126236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Utility of SPECT/CT scan for anatomical localization of pararectal and presacral sentinel nodes in prostate cancer].
    Chícharo de Freitas JR; KleinJan GH; van der Poel HG; van den Berg NS; Vegt E; Stokkel MP; Valdés Olmos RA
    Rev Esp Med Nucl Imagen Mol; 2015; 34(1):19-23. PubMed ID: 25448419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indications for laparoscopic pelvic lymph node dissection in the staging of prostate cancer.
    Patel MI; Katelaris PM
    Aust N Z J Surg; 1995 Apr; 65(4):233-6. PubMed ID: 7536410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Staging pelvic lymphadenectomy for carcinoma of the prostate].
    Rinsho K; Ishikawa S; Nemoto R; Koiso K; Takeshima H; Uchida K
    Hinyokika Kiyo; 1985 Sep; 31(9):1583-7. PubMed ID: 4083215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical staging of prostatic cancer: new modalities.
    Spirnak JP; Resnick MI
    Urol Clin North Am; 1984 May; 11(2):221-35. PubMed ID: 6203203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Extended salvage pelvic and retroperitoneal lymph node dissection due to prostate cancer relapse].
    Osmonov DK; Aksenov AV; Jünemann KP
    Aktuelle Urol; 2013 Jan; 44(1):50-2. PubMed ID: 23325670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
    Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
    Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement.
    Van den Bergh L; Lerut E; Haustermans K; Deroose CM; Oyen R; Isebaert S; Budiharto T; Ameye F; Mottaghy FM; Bogaerts K; Van Poppel H; Joniau S
    Urol Oncol; 2015 Mar; 33(3):109.e23-31. PubMed ID: 25655681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy.
    Flanigan RC; McKay TC; Olson M; Shankey TV; Pyle J; Waters WB
    Urology; 1996 Sep; 48(3):428-32. PubMed ID: 8804497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? A retrospective study.
    Al-Ghazo MA; Ghalayini IF; Al-Azab RS; Bani-Hani I; Barham A; Haddad Y
    Int Braz J Urol; 2010; 36(6):685-91; discussion 691-2. PubMed ID: 21176275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
    BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up.
    Carroll P; Coley C; McLeod D; Schellhammer P; Sweat G; Wasson J; Zietman A; Thompson I
    Urology; 2001 Feb; 57(2):225-9. PubMed ID: 11182325
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.